Dipeptidyl peptidase IV inhibitors and their uses as...

Details Dipeptidyl peptidase IV inhibitors and their uses as... Dipeptidyl peptidase IV inhibitors and their uses as...

2006-09-19

2006-09-19

Campell, Bruce R. (Department: 1654)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C548S530000

Reexamination Certificate

active

07109347

ABSTRACT:
The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for treating conditions mediated by DPIV or DPIV-like enzymes, such as cancer and tumors. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of metastasis and tumor colonization.

REFERENCES:
patent: 2961377 (1960-11-01), Shapiro et al.
patent: 3174901 (1965-03-01), Sterne
patent: 3879541 (1975-04-01), Kabbe et al.
patent: 3960949 (1976-06-01), Ahrens et al.
patent: 4028402 (1977-06-01), Fischer et al.
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 5433955 (1995-07-01), Bredehorst et al.
patent: 5462928 (1995-10-01), Bachovchin et al.
patent: 5512549 (1996-04-01), Chen et al.
patent: 5543396 (1996-08-01), Powers et al.
patent: 5552426 (1996-09-01), Lunn et al.
patent: 5614379 (1997-03-01), MacKellar
patent: 5624894 (1997-04-01), Bodor
patent: 5705483 (1998-01-01), Galloway et al.
patent: 5827898 (1998-10-01), Khandwala et al.
patent: 5939560 (1999-08-01), Jenkins et al.
patent: 6006753 (1999-12-01), Efendic
patent: 6011155 (2000-01-01), Villhauer
patent: 6107317 (2000-08-01), Villhauer
patent: 6110949 (2000-08-01), Villhauer
patent: 6124305 (2000-09-01), Villhauer
patent: 6172081 (2001-01-01), Damon
patent: 6201132 (2001-03-01), Jenkins et al.
patent: 6303661 (2001-10-01), Demuth et al.
patent: 6319893 (2001-11-01), Demuth et al.
patent: 6448282 (2002-09-01), Phillips et al.
patent: 6500804 (2002-12-01), Demuth et al.
patent: 6517824 (2003-02-01), Kohn et al.
patent: 6548481 (2003-04-01), Demuth et al.
patent: 6605589 (2003-08-01), Uckun et al.
patent: 2001/0025023 (2001-09-01), Carr
patent: 2003/0119750 (2003-06-01), Demuth et al.
patent: 25 42 598 (1976-04-01), None
patent: 25 42 598 (1976-04-01), None
patent: 296 075 (1991-11-01), None
patent: 296 075 (1991-11-01), None
patent: 196 16 486 (1997-10-01), None
patent: 196 16 486 (1997-10-01), None
patent: 299 09 210 (1999-10-01), None
patent: 198 26 972 (1999-12-01), None
patent: 0 658 568 (1995-06-01), None
patent: 0 658 568 (1995-06-01), None
patent: 0 708 179 (1996-04-01), None
patent: 0 708 179 (1996-04-01), None
patent: 0 995 440 (2000-04-01), None
patent: 0 995 440 (2000-04-01), None
patent: 1 130 022 (2001-09-01), None
patent: 2 085 665 (1971-12-01), None
patent: 2.085.665 (1971-12-01), None
patent: 2 696 740 (1994-04-01), None
patent: 2 696 740 (1994-04-01), None
patent: 04-288098 (1992-10-01), None
patent: 4334357 (1992-11-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO 91/16339 (1991-10-01), None
patent: WO 91/17767 (1991-11-01), None
patent: WO 93/01812 (1993-02-01), None
patent: WO 93/08259 (1993-04-01), None
patent: WO 93/20061 (1993-10-01), None
patent: WO 95/11689 (1995-05-01), None
patent: WO 95/15309 (1995-06-01), None
patent: WO 95/22327 (1995-08-01), None
patent: WO 95/29691 (1995-11-01), None
patent: WO 97/40832 (1997-11-01), None
patent: WO 97/45117 (1997-12-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 98/22494 (1998-05-01), None
patent: WO 99/41220 (1999-08-01), None
patent: WO 99/41224 (1999-08-01), None
patent: WO 99/46272 (1999-09-01), None
patent: WO 99/61431 (1999-12-01), None
patent: WO 99/62914 (1999-12-01), None
patent: WO 00/01849 (2000-01-01), None
patent: WO 00/10549 (2000-03-01), None
patent: WO 00/53171 (2000-09-01), None
patent: WO 00/53596 (2000-09-01), None
patent: WO 00/58360 (2000-10-01), None
patent: WO 01/09169 (2001-02-01), None
patent: WO 01/32624 (2001-05-01), None
patent: WO 01/34594 (2001-05-01), None
patent: WO 01/62266 (2001-08-01), None
patent: WO 01/62266 (2001-08-01), None
patent: WO 01/74299 (2001-10-01), None
patent: WO 01/89569 (2001-11-01), None
patent: WO 01/94310 (2001-12-01), None
patent: WO 01/97808 (2001-12-01), None
patent: WO 02/13821 (2002-02-01), None
patent: WO 02/20825 (2002-03-01), None
patent: WO 03/016335 (2003-02-01), None
patent: WO 03/070732 (2003-08-01), None
patent: WO 2004/089366 (2004-10-01), None
RA Pederson, et al. Diabetes (1998) 47, pp. 1253-1258.
SI Dawson, Cancer (2004), 100(1), pp. 149-155.
PAGE, NIH Grant NR03915, <http://painconsortium.nih.gov/genderandpain/abstracts/ggpage.htm>, [internet document] accessed Sep. 16, 2005, 2 pages.
R McKie. Cancer Research Set Back a Decade. The Observer Jun. 10, 2001 pp. 1-4.
GB Dermer. Another Anniversary for the War on Cancer. Bio/Technology Mar. 12, 1994 p. 320.
T. Gura. Systems for Identifying New Drugs are Often Faulty. Science (1997) 278 (Nov. 7) 1041-1042.
C Gorman, et al. The Hype and the Hope. Time (1998) 151(19) pp. 40-44. Included HTML copy referenced pp. 1-9.
“cancer” [internet document] accessed Sep. 16, 2005 <http://www.medterms.com>, last reviewed Sep. 18, 2004, 1 page.
W.S. Messer, “Vasopressin and Oxytocin”, web document updated Apr. 3, 2000; http://www.neurosci.pharm.utoledo.edu/MBC3320/vasopressin.htm; 5 pages.
E. Smilek, et al. Proc. Natl. Acad. Sci. USA (1991) 88, pp. 9633-9637.
D. Voet and J.G. Voet. Biochemistry, 2nd Edition.(1995), pp. 235-241.
J. Rudinger. In: Peptide Hormones, JA Parsons, Ed. (1976) 1-7.
U Wesley, et al. Int. J. Cancer. (2004) 109, 855-866.
P Bu{overscore (s)}ec, et al. Int. J. Biochem. Cell Biol. (2004) 36, 408-42.
K Senten, et al. J. Med. Chem. (2003) 46, 5005-5014.
Campbell, I.W.New Antidiabetic Drugs, ed. C.J. Bailey & P.R. Flatt, Smith-Gordon, “Sulphonylureas and metformin: efficacy and inadequacy”. 3:33-51 (1990).
Chemical Abstracts, vol. 115. No. 15, Oct. 14, 1991 Columbus, Ohio, US; abstract No. 149947q, Schoen Ekkehard et al: “Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes”.
Chemical Abstracts, vol. 118, No. 25, Jun. 21, 1993 Columbus, Ohio, US; abstract No. 255342k, Hosoda, et al, “Preparation of N-(heterocyclic Carbonyl)Amino Acids and Analogs as Prolyl Endopeptidase Inhibitors”, Nov. 20, 1992.
Chemical Abstracts, vol. 126, No. 2, Jan. 13, 1997 Columbus, Ohio, US; abstract No. 16161j, Stoeckel A. et al: “Competitive inhibition of proline specific enzymes by amino acid thioxopyrrolidides and thiazolidides”.
Martindale The Extra Pharmacopoeia, 30thEdition, London Pharmaceutical Press, 1993, p. 1619.
Amasheh, S., et al., “Electrophysiological analysis of the function of the mammalian renal peptide transporter expressed in Xenopus Laevis oocytes”.J. Physiol. 504, 169-174 (1997).
Durinx, C.; et al.; “Reference Values for Plasma Dipepidyl-Pepidase IV activity and their Association with Other Laboratory Parameters”.Clin Chem Lab Med 2001, Feb.; 39(2) :155-9, 1 page, Abstract.
Gossrau, R.; “Cytochemistry of Membrane Proteases”.Histochem J, 1985, Jul.; 17 (7) :737-71, 1 page, Abstract.
Hahn, T.; et al.; “Enzyme Histochemical Evidence for the Presence of Potential Blood Pressure Regulating Proteases in Cultured Villous Explants from Human First Trimester Placentae”.Acta Histochem1993, Dec., 95 (2) :185-92, 1 page, Abstract.
Heymann, E. et al., “Had Dipeptidyl Peptidase IV an Effect on Blood Pressure and Coagulation.”Klin Wochenschr, 1984, Jan., 2;62 (1) :2-10, 1 page, Abstract.
Magyar, C.E. et al., “Proximal Tubule Na Transporter Responses are the same during Acute and Chronic Hypertension.”Am J. Physiol Renal Physiol, 2000, Aug.; 279 (2) :F358-69, 1 page, Abstract.
Mentlein, R., et al., “Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV”.Regul. Pept. 49, 133-144 (1993).
Qureshi. N.U.; et al., “Endogenous Neuropeptide Y Mediates Vasoconstriction during Endotoxic and Hemorrhagic Shock”.Regul Pept, 1998, Sep. 25; 75-76:215-20, 1 page, Abstract.
G.G. Duncan,Diseases of Metabolism(Asian edition), “Diabetes Mellitus”, (1996), p. 951-957.
Gutniak et al.,Diabetes Care, “Subcutaneous Injection of the Incretin Hormone Glucagon-LIke Peptide 1 Abolis

Affiliated with

Also associated with

Rating

Dipeptidyl peptidase IV inhibitors and their uses as... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dipeptidyl peptidase IV inhibitors and their uses as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dipeptidyl peptidase IV inhibitors and their uses as... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3586274